Recommended procedures for the treatment and diagnostics of hepatocellular carcinoma

Czech version

Authors: R. Brůha ¹; J. Šperl ¹; P. Urbánek ¹; J. Špičák ²; I. Kiss ³; V. Válek4 ^,6; V. Mejzlík ⁵; M. Oliverius ⁵; E. Honsová ⁷; P. Husa Za Pracovní Skupinu Hcc ^{8 2011}
Authors‘ workplace: Česká hepatologická společnost ČLS JEP ¹; Česká gastroenterologická společnost ČLS JEP ²; Česká onkologická společnost ČLS JEP ³; Česká společnost intervenční radiologie ČLS JEP ⁴; Česká transplantační společnost ⁵; Radiologická společnost ČLS JEP ⁶; Společnost českých patologů ČLS JEP ⁷; Společnost infekčního lékařství ČLS JEP ⁸
Published in: Gastroent Hepatol 2012; 66(2): 83-92
Category: Hepatology: Best Practises

Sources

1. International Agency for Cancer Reseach. GLOBOCAN 2002: http://www-dep.iarc.fr Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (5 Suppl 1): S5–S16.

2. AASLD guidelines for HCC. http://www.aasld.org/practiceguidelines/Documents//Bookmarked%20Practice%20Guidelines//HCCUpdate2010.pdf.

3. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130(7): 417–422.

4. Yuen MF, Tanaka Y, Fong DY et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50(1): 80–88.

5. Lok AS, Seeff LB, Morgan TR et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136(1): 138–148.

6. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336(7650): 924–926.

7. Singal A, Volk ML, Waljee A et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30(1): 37–47.

8. Lok AS, Sterling RK, Everhart JE et al. HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138(2): 493–502.

9. Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. Hepatology 2011; 53(3): 1020–1022.

10. International Consensus group for hepatocellular neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49(2): 658–664.

11. Forner A, Vilana R, Ayuso C et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47(1): 97–104.

12. Sangiovanni A, Manini MA, Iavarone M et al. The diagnostic and economic impact of contrast paging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59(5): 638–644.

13. Edge SB, Byrd DR, Compton CC et al. AJCC Cancer Staging Manual 7th edition. Springer, 2010.

14. Pugh RNH, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60(8): 646–664.

15. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33(2): 464–470.

16. Forner A, Reig ME, de Lope CR et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30(1): 61–74.

17. Llovet, JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25(2): 181–200.

18. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127 (Suppl 1): S268–276.

19. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334(11): 693–699.

20. Livraghi T, Meloni F, Di Stasi M et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008; 47(1): 82–89.

21. Lin SM, Lin CJ, Lin CC et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004; 127: 1714–1723.

22. Cho YK, Kim JK, Kim MY et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49(2): 453–459.

23. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127 (5 Suppl 1): S179–188.

24. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37(2): 429–442.

25. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378–390.

26. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 2009; 10(1): 25–34.